Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem

Location: Jerusalem, IL
No. of patents: 28

Number	Title	Issue Date
7214716	Agonists specific for the peripheral cannabinoid receptor The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bi...	05/08/2007
6949565	Protein kinase inhibitors Novel isoquinoline derivatives which are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes are disclosed. Preferred compounds which are specific inhibitors of protein kinase B are also disclosed. Furthermore, pharmaceutical ...	09/27/2005
6903137	Agonists specific for the peripheral cannabinoid receptor The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bi...	06/07/2005
6864291	Agonists specific for the peripheral cannabinoid receptor The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bi...	03/08/2005
6664368	Inhibition of nuclear import by backbone cyclic peptide analogs The design and the synthesis of backbone cyclic peptide analogs which functionally mimic the nuclear localization signal (NLS) region of macromolecules is disclosed. The principles of the invention are exemplified for the NLS sequences of the human immuno...	12/16/2003
6331560	Tumor necrosis factor alpha (TNF-଱) inhibiting pharmaceuticals Pharmaceutical compositions are described for preventing TNF toxicity, comprising as active ingredient the stereospecific (+) enantiomer having 3S, 4S configuration of delta 6 tetrahydrocannabinol type compounds. The compositions are particularly effectiv...	12/18/2001
6284903	Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them The present invention relates to a novel class of compounds for treating hyperlipidemia, obesity and impaired glucose tolerance/noninsulin dependent diabetes mellitus without adversely affecting energy metabolism, and pharmaceutical compositions comprisin...	09/04/2001
6265375	Conformationally constrained backbone cyclized peptide analogs Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N଱ (ω-functionalized) am...	07/24/2001
6162462	Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient Liposomal bupivacaine compositions are prepared using an ammonium sulfate gradient loading procedure, at a pH which prevents precipitation of the drug from the loading solution. Also described are liposome suspensions comprising `GMV` (giant multivesicula...	12/19/2000
5897879	Sustained-release pharmaceutical system for the delivery of antioxidants The invention relates to a sustained-release pharmaceutical delivery system for the administration of an antioxidant drug to a patient in need of such drug, wherein said delivery system comprises said drug in combination with a polymeric matrix, said matr...	04/27/1999
5891725	Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them The invention relates to synthetic phosphorothioated or partially phosphorothioated oligodeoxynucleotides capable of selectively modulating hemopoietic bone marrow cells development. More particularly, the invention relates to synthetic antisense oligodeo...	04/06/1999
5883293	Conformationally constrained backbone cyclized peptide analogs Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N଱ (ω-functionalized) am...	03/16/1999
5874423	Digitalis-like compounds A human cataractous lens nuclei methanolic extract characterized in that it comprises substances having a molecular weight lower than 3000 daltons, inhibiting ATP hydrolysis by Na+,K+ -ATPase having affinity to the ouabain binding si...	02/23/1999
5858296	Preparation of biologically active molecules by molecular imprinting A method for preparing mimics of a wide variety of drugs and other biologlly active molecules using molecular imprinting techniques, and the mimics produced thereby, is disclosed. Specifically, the mimic is designed by: (i) polymerization of functional m...	01/12/1999
5849742	Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is bas...	12/15/1998
5811392	Conformationally constrained backbone cyclized peptide analogs Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N଱ (ω-functionalized) am...	09/22/1998
5792771	Quinazoline compounds and compositions thereof for the treatment of disease The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is bas...	08/11/1998
5753612	Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists Pharmaceutical preparations for controlling proliferation of ectodermally-derived tissues comprising the specific negative growth factor activin A or an agonist thereof, and their use in methods of treatment of proliferative conditions and wound repair....	05/19/1998
5719264	Conotoxin peptides The present invention is directed to conotoxin peptides having 25-35 amino acids, six cysteines which form three disulfide bonds between the first and fourth, second and fifth, and third and sixth cysteines, respectively. The invention is directed to δ-c...	02/17/1998
5595903	Genetically engineered human acetylcholinesterase Genetically engineered human acetylcholinesterase and antibodies that def the protein are described. These composition may be used in pharmaceutical preparations for treatment and prophylaxis of organo-phosphorous compound poisoning or post-operative apn...	01/21/1997
5552139	Method for the biological control of pollen in plants A method for the biological control of pollen in plants, including the thinning of fruits, reducing seeds in citrus plants and reducing the incidence of shotberries in grapes, by applying an effective amount of activated or inactivated RNase or mixtures o...	09/03/1996
5525634	Colonic drug delivery system A colonic delivery system for delivering a drug to the colon is provided. The system comprises a drug in combination with a matrix, wherein the matrix comprises a saccharide-containing polymer. According to the invention, the matrix is resistant to chemic...	06/11/1996
5486591	Biopolymers derived from hydrolyzable diacid fats A monomeric diacid derivative includes at least two fatty acids coupled by hydrolytically or enzymatically degradable bond. In a biological environment, the bond degrades forming naturally occurring fatty acid products thereby allowing elimination....	01/23/1996
5473103	Biopolymers derived from hydrolyzable diacid fats A monomeric diacid derivative includes at least two fatty acids coupled by a hydrolytically or enzymatically degradable bond. In a biological environment, the bond degrades forming naturally occurring fatty acid products thereby allowing elimination....	12/05/1995
4915944	Novel isolate of trichoderma, fungicidal compositions containing said isolate and use thereof A biological control agent comprising the mycoparasite Trichoderma harzianum T-315 (ATCC No. 20671), which is characterized by fungicidal activity against fungi of the genera Pythium, Rhizoctonia, Sclerotium and Fusarium. This strain is useful for control...	04/10/1990
4713342	Novel isolate of trichoderma, fungicidal compositions containing said isolate and use thereof A biological control agent comprising the mycoparasite Trichoderma harzia T-315 (ATCC No. 20671), which is characterized by fungicidal activity against fungi of the genera Pythium, Phizoctonia, Sclerotium and Fusarium. This strain is useful for controlli...	12/15/1987
4426719	Production of monochromatic x-ray images of x-ray sources and space resolving x-ray spectra The present method and apparatus produces undistorted x-ray images of sources emitting x-rays and especially of certain areas emitting x-rays. Stigmatic monochromatic x-ray images, and x-ray spectra with a spatial resolution along the lines of the spectru...	01/17/1984
4073875	Oxidation of magnesium chloride The present invention relates to the production of chlorine and magnesium oxide. According to the process substantially anhydrous magnesium chloride, containing at least 95% MgCl2, is admixed with particulate magnesium oxide and contacted with ...	02/14/1978

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem